• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ultrahuman raises $17.5M Series B for wearable glucose monitoring tech

August 17, 2021 By Sean Whooley

Ultrahuman Cyborg
[Image from Ultrahuman]
Ultrahuman announced today that it raised $17.5 million in a Series B financing round for its wearable glucose tracking technology.

Bangalore, India-based Ultrahuman develops the Ultrahuman Cyborg, a continuous metabolism tracker designed to help people with diabetes track blood glucose in real-time and optimize their diet and exercise.

The platform goes beyond traditional markers like body mass index, weight and point-in-time blood tests, utilizing biomarkers to tell users how their body reacts to a certain type of food, how to fuel efficiently for exercise and how to eat for better sleep.

“Our mission is ‘to help people optimize their health by providing them access to deeply personalized insights and real-time nudges,'” the company wrote in a news release.

Ultrahuman said the funds raised in the Series B will give the company the ability to launch in new geographies, strengthen its teams and improve its life sciences research capabilities.

Alpha Wave Incubation (AWI), which is backed by DisruptAD and managed by Falcon Edge, Steadview Capital, Nexus Venture Partners, Blume Ventures and Utsav Somani’s iSeed fund all contributed to the financing. Additionally, angel investors, including Tiger Global’s Scott Schleifer, Sandeep Singhal, Kunal Shah, Sujeet Kumar, Deepinder Goyal, Gunjan Patidar, Gaurav Munjal, Revant Bhate, Mohit Gupta, Vikram Dhingra and Roman Saini also participated.

Filed Under: Business/Financial News, Diabetes, Featured, Funding Roundup, Patient Monitoring Tagged With: Ultrahuman

IN CASE YOU MISSED IT

  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS